Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dry eye

- PMLiVE

Shire launches rare disease website

Hereditary angioedema sitesupports its Me, Not HAE campaign

Shire Basingstoke

Shire enters research partnership for rare eye disease

Will work with Foundation Fighting Blindness on treatment for adRP

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

Shire Basingstoke

Silver lining as Shire rare disease programme hits a setback

Alagille syndrome candidate fails to meet phase II targets

Shire Basingstoke

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Shire Basingstoke

Shire links with US hospital for rare disease research

Willwork with Cincinnati Children's Hospital Medical Centre novel therapies

Shire Basingstoke

Shire boosts orphan drug pipeline with Meritage Pharma deal

Firm will also acquire global rights to Meritage’s phase III OBS compound

- PMLiVE

Valeant and Shire said to be evaluating potential Salix bids

Valeant currently in final stages of Provenge acquisition

- PMLiVE

Monica Seles to front Shire’s binge eating disorder campaign

Tennis star experienced condition at height of her success

- PMLiVE

Shire gets FDA nod for first binge-eating treatment

Vyvanse already available as ADHD treatment

- PMLiVE

Relief for Shire as FDA clears NPS’ Natpara

Drug was a key interest as part of NPS takeover

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links